Effects of dietary bioactive compounds on obesity induced inflammation;Mecanismos de ação de compostos bioativos dos alimentos no contexto de processos inflamatórios relacionados à obesidade

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 53, Issue 5, 2009, Pages 646-656

  Bastos, Deborah H M ^a   Rogero, Marcelo M ^a   Arêas, José Alfredo G ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bioactive compounds; Biological availability; Chronic disease; Diet; Inflammation; Obesity

Indexed keywords

ANTIOXIDANT; AUTACOID; CURCUMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOL DERIVATIVE;

ANIMAL; ARTICLE; BIOAVAILABILITY; DIET; FOOD ANALYSIS; HUMAN; INFLAMMATION; METABOLISM; NUTRITION; OBESITY; PHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CURCUMIN; DIET; FOOD ANALYSIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; OBESITY; PHENOLS;

EID: 70349959646     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302009000500017     Document Type: Article

References (53)

1. Sabate J. The contribution of vegetarian diets to health and disease: a paradigm shift? Am J Clin Nutr. 2003;78(3 Suppl):502S-7S.
2. Larsen CS. Animal source foods and human health during evolution. J Nutr. 2003;133(11 Suppl 2):3893S-7S.
3. Minich DM, Bland JS. Dietary management of the metabolic syndrome beyond macronutrients. Nutr Rev. 2008;66(8):429-44.
4. Nestle M. Animal v. plant foods in human diets and health: is thehistorical record unequivocal? Proc Nutr Soc. 1999;58(2):211-8.
5. Holst B, Williamson G. Nutrients and phytochemicals: from bioavailability to bioefficacy beyond antioxidants. Curr Opin Biotechnol. 2008;19(2):73-82.
6. Williamson G, Holst B. Dietary reference intake (DRI) value fordietary polyphenols: are we heading in the right direction? Br JNutr. 2008;99 Suppl 3:S55-8.
7. Jacobs DR, Tapsell LC. Food, not nutrients, is the fundamentalunit in nutrition. Nutr Rev. 2007;65(10):439-50.
8. Frassetto L, Morris RC, Sellmeyer DE, Todd K, Sebastian A. Diet,evolution and aging - The pathophysiologic effects of the postagricultural inversion of the potassiumto-sodium and base-to-chloride ratios in the human diet. Eur J Nutr. 2001;40(5):200-13.
9. Milton K. Nutritional characteristics of wild primate foods: Do thediets of our closest living relatives have lessons for us? Nutrition. 1999;15(6):488-98.
10. Lindeberg S, Jönsson T, Granfeldt Y, Borgstrand E, Soffman J, Sjöström K, et al. A Palaeolithic diet improves glucose tolerancemore than a Mediterraneanlike diet in individuals with ischaemicheart disease. Diabetologia. 2007;50(9):1795-807.
11. Osterdahl M, Kocturk T, Koochek A, Wandell PE. Effects of a shortterm intervention with a paleolithic diet in healthy volunteers. EurJ Clin Nutr. 2008;62(5):682-5.
12. Liu RH. Potential synergy of phytochemicals in cancer prevention:mechanism of action. J Nutr. 2004;134(12 Suppl):3479S-3485S
13. Evans EA, Hirsch JB, Dushenkov S. Phenolics, inflammation andnutrigenomics. J Sci Food Agric. 2006;86(15):2503-2509.
14. Kennedy A, Martinez K, Chuang CC, LaPoint K, McIntosh M. Saturatedfatty acidmediated inflammation and insulin resistance in adipose tissue: mechanisms of action and implications. J Nutr. 2009;139(1):1-4.
15. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumornecrosisfactoralpha - direct role in obesity-linkedinsulin resistance. Science. 1993;259(5091):87-91.
16. Bullo M, CasasAgustench P, MigoCorreig P, Aranceta J, SalasSalvado J. Inflammation, obesity and comorbidities: the role ofdiet. Public Health Nutr. 2007;10(10A):1164-72.
17. Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr. 2008;32(6):638-44.
18. Ferrante AW. Obesityinduced inflammation: a metabolic dialoguein the language of inflammation. J Intern Med. 2007;262(4):408-14.
19. Cancello R, Clément K. Is obesity an inflammatory illness? Roleof lowgrade inflammation and macrophage infiltration in humanwhite adipose tissue. BJOG. 2006;113(10):1141-7.
20. Cave MC, Hurt RT, Frazier TH, Matheson PJ, Garrison RN, McClain CJ, et al. Obesity, inflammation, and the potential application ofpharmaconutrition. Nutr Clin Pract. 2008;23(1):16-34.
21. Rogero MM, Tirapegui J, Vinolo MA, Borges MC, de Castro IA, Pires IS, et al. Dietary glutamine supplementation increases theactivity of peritoneal macrophages and hemopoiesis in early-weaned mice inoculated with Mycobacterium bovis bacillusCalmetteGuérin. J Nutr. 2008;138(7):1343-8.
22. Rogero MM, Borelli P, Vinolo MA, Fock RA, de Oliveira Pires IS, Tirapegui J. Dietary glutamine supplementation affects macrophage function, hematopoiesis and nutritional status in earlyweaned mice. Clin Nutr. 2008;27(3):386-97.
23. Lumeng CN, Deyoung SM, Saltiel AR. Macrophages block insulin action in adipocytes by altering expression of signaling andglucose transport proteins. Am J Physiol Endocrinol Metab. 2007;292(1):E166-74.
24. Baud V, Karin M. OPINION: is NF-kappa B a good target for cancertherapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009;8(1):33-40.
25. Rahman I, Biswas SK, Kirkham PA. Regulation of inflammationand redox signaling by dietary polyphenols. Biochem Pharmacol. 2006;72(11):1439-52.
26. Bensinger SJ, Tontonoz P. Integration of metabolism andinflammation by lipidactivated nuclear receptors. Nature. 2008;454(7203):470-7.
27. Duval C, Müller M, Kersten S. PPAR alpha and dyslipidemia. Biochim Biophys Acta. 2007;1771(8):961-71.
28. Ordovas JM. Genetic interactions with diet influence the risk ofcardiovascular disease. Am J Clin Nutr. 2006;83(2):443S-446S.
29. Singh S, Aggarwal BB. Activation of transcription factor nfkappab is suppressed by curcumin (Diferuloylmethane). J BiolChem. 1995;270(42):24995-25500.
30. Rahman I, Biswas SK, Kirkham PA. Regulation of inflammationand redox signaling by dietary polyphenols. Biochem Pharmacol. 2006;72(11):1439-52.
31. Aggarwal BB, Shishodia S. Molecular targets of dietary agentsfor prevention and therapy of cancer. Biochem Pharmacol. 2006;71(10):1397-421.
32. Hatcher H, Planalp R, Cho J, Tortia FM, Torti SV. Curcumin: Fromancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65(11):1631-52.
33. Góngora L, Giner RM, Máñez S, Recio MC, Schinella G, et al. Effectsof caffeoyl conjugates of isoprenylhydroquinone glucoside andquinic acido n leukocyte function. Life Sci. 2002;71(25):2995-3004.
34. Muriel P. NF-KB in liver diseases: a target for drug therapy. J ApplToxicol. 2009;29(2):91-100.
35. Gugliucci A, Bastos DHM. Chlorogenic acid protects oaraoxonase 1activity in high density lipoprotein from inactivation caused by physiological concentrations of hypochlorite. Fitoterapia. 2009;80:138-142.
36. Gugliucci A, Bastos DHM, Schulze J, Souza MFF. Caffeic andchlorogenic acids in Ilex paraguariensis extracts are the main inhibitors of AGE generation by methylglyoxal in model proteins. Fitoterapia. 2009 (in press. doi:10.1016/j.fitote.2009.04.007).
37. Park HJ, Jeong SK, Kim SR, Bae SK, Kim WS, Jin SD, et al. Resveratrol inhibits Porphyromonas gingivalis lipopolysaccharideinduced endothelial adhesion molecule expression by suppressing NF-kappaB activation. Arch Pharm Res. 2009;32(4):583-91.
38. Kang SS, Cuendet M, Endringer DC, Croy VL, Pezzuto JM, Lipton MA. Synthesis and biological evaluation of a library of resveratrolanalogues as inhibitors of COX-1, COX-2 and NF-kappa B. BioorgMed Chem. 2009;17(3):1044-54.
39. Pae HO, Jeong SO, Kim HS, Kim SH, Song YS, Kim SK, et al. Dimethoxycurcumin, a synthetic curcumin analogue with higher metabolic stability, inhibits NO production, inducible NO synthaseexpression and NF-kappaB activation in RAW264.7 macrophagesactivated with LPS. Mol Nutr Food Res. 2008;52(9):1082-91.
40. Kasinski AL, Du Y, Thomas SL, Zhao J, Sun SY, Khuri FR, et al. Inhibition of IkappaB kinasenuclear factorkappaB signaling pathwayby 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel analog of curcumin. Mol Pharmacol. 2008;74(3):654-61.
41. Lambert JD, Sang SM, Yang CS. Biotransformation of green teapolyphenols and the biological activities of those metabolites. Mol Pharm. 2007;4(6):819-25.
42. Lambert JD, Yang CS. Cancer chemopreventive activity and bioavailability of tea and tea polyphenols. Mutat Res. 2003;523-524:201-8
43. Yang CS, Maliakal P, Meng XF. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol. 2002;42:25-54.
44. Porrini M, Riso P. Factors influencing the bioavailability of antioxidants in foods: A critical appraisal. Nutr Metab Cardiovasc Dis. 2008;18(10):647-50.
45. Karakaya S. Bioavailability of phenolic compounds. Crit Rev FoodSci Nutr. 2004;44(6):453-64.
46. Spencer JPE, Mohsen MMA, Minihane AM, Mathers JC. Biomarkers of the intake of dietary polyphenols: strengths, limitationsand application in nutrition research. Br J Nutr. 2008;99(1):12-22.
47. Olthof MR, Hollman PCH, Buijsman MNCP, van Amelsvoort JMM, Katan MB. Chlorogenic acid, quercetin-3-rutinoside and blacktea phenols are extensively metabolized in humans. J Nutr. 2003;133(6):1806-14.
48. Tomas-Barberen FA, Clifford MN. Flavanones, chalcones and dihydrochalcones - nature, occurrence and dietary burden. J SciFood Agric. 2000;80(7):1073-80.
49. Gonthier MP, Verny MA, Besson C, Remesy C, Scalbert A. Chlorogenic acid bioavailability largely depends on its metabolism bythe gut microflora in rats. J Nutr. 2003;133:1853-9.
50. Clifford MN. Chlorogenic acids and other cinnamates - nature,occurrence, dietary burden, absorption and metabolism. J SciFood Agric. 2000;80(7):1033-43.
51. Rechner AR, Spencer JPE, Kuhnle G, Hahn U, RiceEvans CA. Novel biomarkers of the metabolism of caffeic acid derivatives invivo. Free Radic Biol Med. 2001;30(11):1213-22.
52. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807-18.
53. Wenzel E, Somoza V. Metabolism and bioavailability of transresveratrol. Mol Nutr Food Res. 2005;49(5):472-81